NUVB vs. LLY

Last updated Apr 2, 2026

Compare and contrast key facts about Nuvation Bio Inc. (NUVB) and Eli Lilly and Company (LLY).

Performance

NUVB vs. LLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nuvation Bio Inc. (NUVB) and Eli Lilly and Company (LLY). The values are adjusted to include any dividend payments, if applicable.

NUVB vs. LLY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
NUVB Nuvation Bio Inc.	-49.67%	236.84%	76.16%	-21.35%	-77.41%	-27.35%	17.00%
LLY Eli Lilly and Company	-11.03%	40.25%	33.30%	60.91%	34.26%	66.08%	13.50%

Fundamentals

Market Cap NUVB : $1.55B LLY : $857.16B
EPS NUVB : -$0.60 LLY : $22.96
PS Ratio NUVB : 24.56 LLY : 13.16
PB Ratio NUVB : 5.08 LLY : 32.30
Total Revenue (TTM) NUVB : $62.90M LLY : $65.18B
Gross Profit (TTM) NUVB : $54.46M LLY : $54.62B
EBITDA (TTM) NUVB : -$199.90M LLY : $27.94B

Returns By Period

In the year-to-date period, NUVB achieves a -49.67% return, which is significantly lower than LLY's -11.03% return.

NUVB

• 1D: 5.13%
• 1M: -22.77%
• YTD: -49.67%
• 6M: 21.89%
• 1Y: 157.71%
• 3Y*: 39.54%
• 5Y*: -15.06%
• 10Y*: —

LLY

• 1D: 3.78%
• 1M: -6.23%
• YTD: -11.03%
• 6M: 16.00%
• 1Y: 19.42%
• 3Y*: 41.64%
• 5Y*: 40.20%
• 10Y*: 31.41%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NUVB vs. LLY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NUVB

NUVB Risk / Return Rank: 84
NUVB Sharpe Ratio Rank: 86
NUVB Sortino Ratio Rank: 85
NUVB Omega Ratio Rank: 85
NUVB Calmar Ratio Rank: 83
NUVB Martin Ratio Rank: 81

LLY

LLY Risk / Return Rank: 54
LLY Sharpe Ratio Rank: 57
LLY Sortino Ratio Rank: 52
LLY Omega Ratio Rank: 53
LLY Calmar Ratio Rank: 54
LLY Martin Ratio Rank: 54

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NUVB vs. LLY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nuvation Bio Inc. (NUVB) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NUVB	LLY	Difference
Sharpe ratio Return per unit of total volatility	1.67	0.46	+1.21
Sortino ratio Return per unit of downside risk	2.46	0.90	+1.55
Omega ratio Gain probability vs. loss probability	1.34	1.13	+0.21
Calmar ratio Return relative to maximum drawdown	2.72	0.54	+2.17
Martin ratio Return relative to average drawdown	6.64	1.33	+5.31
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NUVB vs. LLY - Sharpe Ratio Comparison

The current NUVB Sharpe Ratio is 1.67, which is higher than the LLY Sharpe Ratio of 0.46. The chart below compares the historical Sharpe Ratios of NUVB and LLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NUVB	LLY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.67	0.46	+1.21
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.20	1.26	-1.45
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	1.06	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.18	0.57	-0.75

Correlation

The correlation between NUVB and LLY is 0.17, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

NUVB vs. LLY - Dividend Comparison

NUVB has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.65%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
NUVB Nuvation Bio Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
LLY Eli Lilly and Company	0.65%	0.56%	0.67%	0.78%	1.07%	1.23%	1.75%	1.96%	1.94%	2.46%	2.77%	2.37%

Drawdowns

NUVB vs. LLY - Drawdown Comparison

The maximum NUVB drawdown since its inception was -93.39%, which is greater than LLY's maximum drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for NUVB and LLY.

Drawdown Indicators

	NUVB	LLY	Difference
Max Drawdown Largest peak-to-trough decline	-93.39%	-68.24%	-25.15%
Max Drawdown (1Y) Largest decline over 1 year	-57.55%	-30.26%	-27.29%
Max Drawdown (5Y) Largest decline over 5 years	-93.35%	-34.48%	-58.87%
Max Drawdown (10Y) Largest decline over 10 years	—	-34.48%	—
Current Drawdown Current decline from peak	-69.05%	-13.86%	-55.19%
Average Drawdown Average peak-to-trough decline	-65.43%	-19.25%	-46.18%
Ulcer Index Depth and duration of drawdowns from previous peaks	23.53%	12.39%	+11.14%

Volatility

NUVB vs. LLY - Volatility Comparison

Nuvation Bio Inc. (NUVB) has a higher volatility of 16.34% compared to Eli Lilly and Company (LLY) at 9.94%. This indicates that NUVB's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NUVB	LLY	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.34%	9.94%	+6.40%
Volatility (6M) Calculated over the trailing 6-month period	69.18%	26.02%	+43.16%
Volatility (1Y) Calculated over the trailing 1-year period	95.04%	42.60%	+52.44%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	76.00%	32.17%	+43.83%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	73.56%	29.82%	+43.74%

Financials

NUVB vs. LLY - Profitability Comparison

The chart below illustrates the profitability comparison between Nuvation Bio Inc. and Eli Lilly and Company over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

NUVB - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Nuvation Bio Inc. reported a gross profit of 41.44M and revenue of 41.87M. Therefore, the gross margin over that period was 99.0%.

LLY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported a gross profit of 16.41B and revenue of 19.29B. Therefore, the gross margin over that period was 85.1%.

NUVB - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Nuvation Bio Inc. reported an operating income of -34.04M and revenue of 41.87M, resulting in an operating margin of -81.3%.

LLY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported an operating income of 8.78B and revenue of 19.29B, resulting in an operating margin of 45.5%.

NUVB - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Nuvation Bio Inc. reported a net income of -36.59M and revenue of 41.87M, resulting in a net margin of -87.4%.

LLY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported a net income of 6.64B and revenue of 19.29B, resulting in a net margin of 34.4%.